YS Biopharma Co. Ltd.

What does YS Biopharma Co. Ltd. do?

YS Biopharma Co. Ltd. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $19 million and a net loss of $25 million for Q1 2024, with a market cap of $18.51 million. Key financial metrics include a debt equity ratio of 0.30 and a return on equity of -22.61%.

Overview:<BR>YS Biopharma Co. Ltd. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 19 Million (Quarterly Results - Mar 2024) <BR>Most recent Net Profit: -25 Million (Quarterly Results - Mar 2024) <BR>Market-cap: USD 18.51 Million (Micro Cap)<BR><BR>Key Metrics:<BR>Debt Equity: 0.30 <BR>Return on Equity: -22.61% <BR>Price to Book: 0.22 <BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold YS Biopharma Co. Ltd.?

Is YS Biopharma Co. Ltd. overvalued or undervalued?

As of May 10, 2024, YS Biopharma Co. Ltd. is considered overvalued and risky due to its negative earnings performance, a concerning -22.61% Return on Equity, and a year-to-date stock decline of -71.97%, contrasting sharply with its peers and the S&P 500.

As of 10 May 2024, YS Biopharma Co. Ltd. has moved from a fair to a risky valuation grade, indicating a significant deterioration in its investment appeal. The company is currently assessed as overvalued given its financial metrics, particularly with a Price to Book Value of 0.23 and an EV to EBITDA ratio of 3.60, which, while low, is overshadowed by its negative earnings performance. The Return on Equity (ROE) stands at a concerning -22.61%, highlighting the company's struggles in generating profit relative to shareholder equity.<BR><BR>In comparison to its peers, YS Biopharma's valuation appears unfavorable. For instance, Champions Oncology, Inc. is rated attractive with a P/E ratio of 17.32, while YS Biopharma's valuation metrics reflect a risky outlook with a negative P/E ratio of -0.99. Additionally, the company's stock performance has been dismal, with a year-to-date return of -71.97%, starkly contrasting with the S&P 500's positive return of 2.44% over the same period. Overall, the combination of poor financial ratios and negative stock performance suggests that YS Biopharma is overvalued in the current market context.

Is YS Biopharma Co. Ltd. technically bullish or bearish?

As of August 11, 2025, YS Biopharma Co. Ltd. is in a mildly bearish trend, with daily moving averages indicating bearishness, while weekly indicators show mild bullishness, and it has underperformed the S&P 500 with a year-to-date return of -77.15%.

As of 11 August 2025, the technical trend for YS Biopharma Co. Ltd. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend, while the weekly MACD and KST show mildly bullish signals. However, the Bollinger Bands and OBV are bearish, and Dow Theory indicates a mildly bearish monthly trend. The stock has significantly underperformed against the S&P 500 across multiple periods, with a year-to-date return of -77.15% compared to the S&P 500's 12.22%.